Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

DAVID F. Archer

Showing results (31-40 of 175) with videos related to

Pageof 18
Sort By:
Expert Review of Clinical Pharmacology|July 9, 2019
A combined, bioidentical, oral, 17β-estradiol and progesterone capsule for the treatment of moderate to severe vasomotor symptoms due to menopauseDavid F Archer, Brian A Bernick, Sebastian Mirkin
Contraception|August 2, 2015
Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerabilityDavid F Archer, Hans-Joachim Ahrendt, Dominique Drouin
Menopause (New York, N.Y.)|May 17, 2017
Ospemifene's effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial dataDavid F Archer, Corrado Altomare, Wei Jiang, et al.
Contraception|February 5, 2013
Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessmentFrank Z Stanczyk, David F Archer, Bhagu R Bhavnani
Menopause (New York, N.Y.)|July 1, 2014
Endometrial safety of ospemifene: results of the phase 2/3 clinical development programGinger D Constantine, Steven R Goldstein, David F Archer
The Journal of Steroid Biochemistry and Molecular Biology|March 22, 2017
Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10μg estradiol on symptoms of vulvovaginal atrophyDavid F Archer, Fernand Labrie, Marlene Montesino, et al.
Journal of Reproductive Immunology|October 3, 2006
RETRACTED: Doxycycline alters the expression of matrix metalloproteases in the endometrial cells exposed to ovarian steroids and pro-inflammatory cytokineRongxiu Li, Xiaoping Luo, David F Archer, et al.
Contraception and Reproductive Medicine|December 5, 2017
Heavy menstrual bleeding diagnosis and medical managementIntira Sriprasert, Tarita Pakrashi, Thomas Kimble, et al.
Fertility and Sterility|January 9, 2004
Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone, and 17beta-estradiol on vascular endothelial growth factor isomers 121 and 165 in Ishikawa cellsDavid F Archer, Francisco J Navarro, Susan Leslie, et al.
Contraception|November 20, 2012
Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity and exerciseDavid F Archer, Frank Z Stanczyk, Arkady Rubin, et al.
Pageof 18

Showing results (31-40 of 175) with videos related to

Sort By:
Pageof 18
Expert Review of Clinical Pharmacology|July 9, 2019
A combined, bioidentical, oral, 17β-estradiol and progesterone capsule for the treatment of moderate to severe vasomotor symptoms due to menopauseDavid F Archer, Brian A Bernick, Sebastian Mirkin
Contraception|August 2, 2015
Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerabilityDavid F Archer, Hans-Joachim Ahrendt, Dominique Drouin
Menopause (New York, N.Y.)|May 17, 2017
Ospemifene's effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial dataDavid F Archer, Corrado Altomare, Wei Jiang, et al.
Contraception|February 5, 2013
Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessmentFrank Z Stanczyk, David F Archer, Bhagu R Bhavnani
Menopause (New York, N.Y.)|July 1, 2014
Endometrial safety of ospemifene: results of the phase 2/3 clinical development programGinger D Constantine, Steven R Goldstein, David F Archer
The Journal of Steroid Biochemistry and Molecular Biology|March 22, 2017
Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10μg estradiol on symptoms of vulvovaginal atrophyDavid F Archer, Fernand Labrie, Marlene Montesino, et al.
Journal of Reproductive Immunology|October 3, 2006
RETRACTED: Doxycycline alters the expression of matrix metalloproteases in the endometrial cells exposed to ovarian steroids and pro-inflammatory cytokineRongxiu Li, Xiaoping Luo, David F Archer, et al.
Contraception and Reproductive Medicine|December 5, 2017
Heavy menstrual bleeding diagnosis and medical managementIntira Sriprasert, Tarita Pakrashi, Thomas Kimble, et al.
Fertility and Sterility|January 9, 2004
Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone, and 17beta-estradiol on vascular endothelial growth factor isomers 121 and 165 in Ishikawa cellsDavid F Archer, Francisco J Navarro, Susan Leslie, et al.
Contraception|November 20, 2012
Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity and exerciseDavid F Archer, Frank Z Stanczyk, Arkady Rubin, et al.
Pageof 18